Vertex Pharmaceuticals Inc (VRTX)

116.59
NASDAQ : Health Care
Prev Close 116.59
Day Low/High 0.00 / 0.00
52 Wk Low/High 71.46 / 121.96
Avg Volume 1.93M
Exchange NASDAQ
Shares Outstanding 249.07M
Market Cap 29.62B
EPS -0.50
P/E Ratio 169.91
Div & Yield N.A. (N.A)

Latest News

Vertex To Present At The UBS Healthcare Conference On May 23

Vertex To Present At The UBS Healthcare Conference On May 23

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the UBS Healthcare Conference on Tuesday, May 23, 2017 at 11:00 a.

FDA Approves KALYDECO® (ivacaftor) For More Than 900 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutations

FDA Approves KALYDECO® (ivacaftor) For More Than 900 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutations

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.

Cramer: These Sectors Look Bullish (Part III)

Cramer: These Sectors Look Bullish (Part III)

From Abbott Labs to Wynn, these names rate checking out.

Cramer: There Are Powerful Themes in Several Bull Markets

Cramer: There Are Powerful Themes in Several Bull Markets

It's a wonder to me how split this market really is.

Vertex Grants $1 Million To 15 Non-profit Organizations To Advance Initiatives For People Living With Cystic Fibrosis

Vertex Grants $1 Million To 15 Non-profit Organizations To Advance Initiatives For People Living With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the grant recipients for its 2017 Cystic Fibrosis (CF) Circle of Care program, an initiative that funds innovative, patient-centric programs for the CF...

Analysts' Actions -- Adobe, AMD, Chegg, Okta and More

Analysts' Actions -- Adobe, AMD, Chegg, Okta and More

Here are Tuesday's top research calls, including new coverage of Adobe and Okta, a downgrade for Advanced Micro Devices and an upgrade for Chegg.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AIMC, CMRE, COG, CVX, HMC, KOF, MGM, MITK, MPLX, NTL, PSX, PXLW, TROW, VRTX Downgrades: AGCO, DRAD, DXR, HTBI, HUBG, IIJI, LII, ROIC, SKY, VSEC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Biotech Movers: CEO Exit, Tea Leaf Reading Prompts Surge in Sarepta Shares

Biotech Movers: CEO Exit, Tea Leaf Reading Prompts Surge in Sarepta Shares

Sarepta Therapeutics and Vertex Pharmaceuticals and Endo Pharmaceuticals were among the biotech stock movers Friday morning.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Vertex Reports First-Quarter 2017 Financial Results

Vertex Reports First-Quarter 2017 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2017.

Vertex To Announce First Quarter 2017 Financial Results On April 27

Vertex To Announce First Quarter 2017 Financial Results On April 27

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2017 financial results on Thursday, April 27, 2017 after the financial markets close.

Protalix Cystic Fibrosis Drug Study Results Worsen Over Time

Protalix Cystic Fibrosis Drug Study Results Worsen Over Time

The Protalix medicine alidornase alfa is designed to help cystic fibrosis patients clear their lungs by making mucus thin and loose.

Did Corbus Investors Get Thrown Off by a Red Herring?

Did Corbus Investors Get Thrown Off by a Red Herring?

Investors ran for the exits after analysts pointed out that glowing Phase 2 study results for Corbus actually weren't that great. But a better story lies behind this biotech play.

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.

Cramer: Stay the Course, but Keep Cash Handy

Cramer: Stay the Course, but Keep Cash Handy

It's pretty normal to have profit-taking after such a strong first quarter.

Here Are Some of the Top Health Care Stocks in the First Quarter

Here Are Some of the Top Health Care Stocks in the First Quarter

Illumina, Centene, Community Health, Incyte and Vertex were among the healthcare stocks that did well in the first quarter.

Corbus Pharma Drug Shows No Clinical Benefit for Cystic Fibrosis Patients

Corbus Pharma Drug Shows No Clinical Benefit for Cystic Fibrosis Patients

Corbus Pharmaceuticals waves a sea of hands in front of investors' eyes Thursday to obscure dismal results from another mid-stage study of its experimental anti-inflammatory drug anabasum.

Closing Bell: Barclays Bets on Alphabet Growth; Dow Falls, S&P 500 and Nasdaq Rise

Closing Bell: Barclays Bets on Alphabet Growth; Dow Falls, S&P 500 and Nasdaq Rise

A rally in crude oil gave rise to the energy sector in a mixed day of trading.

Crude Rally Boosts Energy Stocks, S&P 500 Inches Higher

Crude Rally Boosts Energy Stocks, S&P 500 Inches Higher

The S&P 500 inches higher in mixed trading Wednesday as a rally in crude helps the energy sector.

Vertex Pharmaceuticals Reaches Upside Price Target

Vertex Pharmaceuticals Reaches Upside Price Target

Base building pays off.

Dow Under Pressure, Nasdaq Rises on Gains in Amazon, Google

Dow Under Pressure, Nasdaq Rises on Gains in Amazon, Google

Stocks are mixed on Wednesday as financials retreat again while tech names move higher.

Biotech Premarket Movers: Vertex, Sangamo, Depomed

Biotech Premarket Movers: Vertex, Sangamo, Depomed

Vertex Pharmaceuticals, Sangamo Therapeutics and Depomed were among the biotech stock movers in premarket trading on Wednesday.

Stock Futures Edge Higher as U.K. Invokes Article 50 in First Step of Brexit

Stock Futures Edge Higher as U.K. Invokes Article 50 in First Step of Brexit

Stock futures edge higher on Wednesday as markets await the United Kingdom taking the first step to formally remove itself from the European Union.

Analysts' Actions -- Facebook, Amazon, Alphabet, Twitter and More

Analysts' Actions -- Facebook, Amazon, Alphabet, Twitter and More

Here are Wednesday's top research calls, including a downgrade of Twitter and new coverage of Facebook, Amazon and Alphabet.

Vertex Pharma Shares Higher on Impressive Trial Results for New Cystic Fibrosis Drug

Vertex Pharma Shares Higher on Impressive Trial Results for New Cystic Fibrosis Drug

Vertex to seek marketing approval for new 'teza/iva' combination therapy for cystic fibrosis patients.

Why Concert Pharmaceuticals Is Music to Investors' Ears

Why Concert Pharmaceuticals Is Music to Investors' Ears

This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.

What You Must Know About Cystic Fibrosis Drug CTP-656

What You Must Know About Cystic Fibrosis Drug CTP-656

Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.

Vertex Pharma Acquires Long-Acting Version of Cystic Fibrosis Drug From Concert Pharma

Vertex Pharma Acquires Long-Acting Version of Cystic Fibrosis Drug From Concert Pharma

The convenience of a once-daily version of Kalydeco is important to Vertex because it has the potential to simplify dosing of combination regimens the company has in development.